BurundiTuberculosis profile
Population  2014 11 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.5 (1.8–3.3) 23 (17–30)
Mortality (HIV+TB only) 0.69 (0.57–0.82) 6.4 (5.3–7.5)
Prevalence  (includes HIV+TB) 21 (11–34) 195 (105–313)
Incidence  (includes HIV+TB) 14 (13–15) 126 (116–136)
Incidence (HIV+TB only) 1.9 (1.6–2.1) 17 (15–20)
         
Case detection, all forms (%) 53 (49–58)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.2 (0.3–4.1) 11 (6.2–16)
MDR-TB cases among notified pulmonary
TB cases
110 (15–200) 32 (18–45)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 4 265   206
Pulmonary, clinically diagnosed 653   0
Extrapulmonary 2 102   0
       
Total new and relapse 7 226    
Previously treated, excluding relapses 83    
Total cases notified 7 309    
Among 7 020 new cases:
528 (8%) cases aged under 15 years; male:female ratio: 1.8
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 289 (7%) 60 (21%) 289
Laboratory-confirmed RR-/MDR-TB cases     48
Patients started on MDR-TB treatment ***     49
TB/HIV 2014 Number (%)
TB patients with known HIV status 6 654 (91)
HIV-positive TB patients 901 (14)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 873 (97)
HIV-positive TB patients on antiretroviral therapy (ART) 611 (68)
HIV-positive people screened for TB 976  
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (91) 7 547
Previously treated cases, excluding relapse, registered in 2013 (84) 80
HIV-positive TB cases, all types, registered in 2013 (87) 977
RR-/MDR-TB cases started on second-line treatment in 2012 (92) 36
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 1.6
Culture (per 5 million population) 0.5
Drug susceptibility testing (per 5 million population) 0.5
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? Yes, in and outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) <1
% Funded domestically 0%
% Funded internationally 100%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-04 Data: www.who.int/tb/data